Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2016

Description: Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2016

Summary

‘Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2016’, provides in depth analysis on Calcitonin Gene Related Peptide (CGRP) targeted pipeline therapeutics.

The report provides comprehensive information on the Calcitonin Gene Related Peptide (CGRP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
- The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Calcitonin Gene Related Peptide (CGRP) Overview
Therapeutics Development
Calcitonin Gene Related Peptide (CGRP) - Products under Development by Stage of Development
Calcitonin Gene Related Peptide (CGRP) - Products under Development by Therapy Area
Calcitonin Gene Related Peptide (CGRP) - Products under Development by Indication
Calcitonin Gene Related Peptide (CGRP) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Calcitonin Gene Related Peptide (CGRP) - Products under Development by Companies
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
Alder Biopharmaceuticals Inc.
BCN Peptides, S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
BCN Peptides, S.A.
Teva Pharmaceutical Industries Ltd.
Noxxon Pharma AG
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
ALD-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DD-04107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXL-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olcegepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEV-48125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide (CGRP) - Dormant Projects
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
Calcitonin Gene Related Peptide (CGRP) - Featured News & Press Releases
Apr 12, 2016: Teva to Present Data on TEV-48125 at 68th AAN Annual Meeting

Mar 28, 2016: Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine

Feb 09, 2016: Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization

Oct 13, 2015: Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine

Sep 30, 2015: Important New Data from Teva's TEV-48125 Phase 2B Migraine Program Published in Lancet Neurology in Back-to-Back Articles

Jun 18, 2015: Teva to Present New Findings at the American Headache Society Meeting - Analysis of Migraine Phase IIb Studies Provides Novel Insights into TEV-48125 Efficacy and Safety in Both Episodic & Chronic Migraine

Jun 17, 2015: Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study

May 15, 2015: Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of the International Headache Society

May 14, 2015: Teva Presents Further Data from Phase IIb with TEV-48125 in Chronic Migraine at the International Headache Society Congress (IHC): Efficacy and Safety Results at All Doses and Endpoints Present Robust Case for Progression to Phase III

May 06, 2015: Alder Announces Presentations at 17th Congress of the International Headache Society on Data from ALD403 Clinical Trials

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Alder Biopharmaceuticals Inc., H1 2016
Pipeline by BCN Peptides, S.A., H1 2016
Pipeline by Boehringer Ingelheim GmbH, H1 2016
Pipeline by Eli Lilly and Company, H1 2016
Pipeline by BCN Peptides, S.A., H1 2016
Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
Pipeline by Noxxon Pharma AG, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd., H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Ordering:
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3743726/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>USD 3500</td>
</tr>
<tr>
<td>EnterpriseWide:</td>
<td>USD 10500</td>
</tr>
<tr>
<td>Site License:</td>
<td>USD 7000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ]   Mrs [ ]   Dr [ ]   Miss [ ]   Ms [ ]   Prof [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World